A secondary analysis of data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial suggests the use of aspirin ≥3 per month is associated with a reduction in all-cause and cancer mortality in older adults.
The cohort study examined trial data collected from 146,152 participants aged ≥65 years at baseline (1993-2001). Median follow-up was 12.5 years.
Compared with no use, aspirin use 1-3 times/month was associated with reduced risk of all-cause (HR 0.84; 95% CI 0.80-0.88; P<.001 and cancer ci p mortality particularly for gastrointestinal colorectal>
Aspirin use ≥3 times/week was associated with reductions in all-cause (HR 0.81; 95% CI 0.80-0.83; P<.001 cancer mortality ci p reductions in risk were greater participants with gastrointestinal and colorectal>
Among those with a BMI of 20-24.9 kg/m2, aspirin ≥3 times/week was associated with reductions in all-cause (HR 0.82; 95% CI 0.78-0.85; P<.001 and cancer ci p mortality. similar reductions were seen in those with bmi kg>2 group.
Dosage information was limited and therefore not included in the analysis.